Items Tagged ‘Enfortumab vedotin’

April 3, 2018

Breakthrough Therapy Designation Awarded for Enfortumab Vedotin in Locally Advanced or Metastatic Bladder Cancer


CancerConnect News: The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin for patients with locally advanced or metastatic urothelial (bladder) cancer who were previously treated with checkpoint inhibitors. Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended to treat a […]

View full entry

Tags: Bladder Cancer, checkpoint inhibitors, Enfortumab vedotin, News, PD-1, precision cancer medicines